Optimizing AAV Manufacturing at 2000 L Scale: Smart. Scalable. Reliable.
The gene therapy industry continues to expand rapidly, with treatments targeting broader indications and larger patient populations. Therefore the pressure to deliver scalable and cost-effective manufacturing processes is a priority. Adeno-associated virus (AAV) production relying on transient transfection of HEK293 cells remains the trusted and proven strategy to develop these therapies.
Currently, scale of production ranges from 200 L to 1,000 L scale depending on the clinical stage of the therapies. Moving beyond this threshold for larger patient populations—toward 2,000 L scale or more—can be successfully achieved with smart, scalable, performance-driven materials, technologies, and supporting services at every step, from discovery stage to late stage clinical and commercial scales.
